SF3B1 and myelodysplastic syndrome: More recently, Kanagal-Shamanna et al. found that only the p.Lys700Glu mutation independently predicts better overall survival in MDS, suggesting that the identification of this SF3B1 mutation type is important for risk stratification [32].